WALTHAM, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the commercial launch of TangenX® SC, the industry’s first holder-free, self-contained Tangential Flow Filtration (TFF) device. The technology is especially suited to the manufacture of biologics where fully closed systems are critical or ideal, including antibody drug conjugates (ADCs), viral vectors, nucleic acids and lipid nanoparticles, and can also be applied to monoclonal antibody, and recombinant protein production. TangenX SC is not only transformative, it is also a milestone achievement in the advancement of downstream flat sheet TFF technology for ultrafiltration and diafiltration (UF/DF), which is performed in nearly every biopharmaceutical manufacturing process to concentrate and purify drug.
Christine Gebski, Senior Vice President, Filtration and Chromatography at Repligen, said, “TangenX SC pushes the boundaries of TFF innovation, offering clear advantages to virtually any user of flat sheet TFF. The holder-free TangenX SC device simplifies and streamlines downstream flat sheet UF/DF processes like never before. Users can trust that the quality and consistency of their TFF processes remain uncompromised while enjoying the benefits of this innovative technology.”
Compared with traditional flat sheet TFF cassettes, “plug-and-play” TangenX SC self-contained devices offer several key advantages that drive significant efficiency and productivity gains:
This next-generation technology provides Repligen’s biopharmaceutical manufacturing customers with an expanded selection of flat sheet TFF offerings, beyond its TangenX SIUS® and SIUS Gamma single-use cassettes and PRO reusable cassettes.
About Repligen Corporation
Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are “inspiring advances in bioprocessing” for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, France, Germany, Ireland, the Netherlands and Sweden. For more information, please visit www.repligen.com, and follow us on LinkedIn.
Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of the federal securities laws. Investors are cautioned that statements in this press release which are not strictly historical statements including, without limitation, statements identified by words like “believe,” “expect,” “may,” “will,” “should,” “seek,” or “could” and similar expressions, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including risks discussed from time to time in our filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to update any forward-looking statements, except as required by law.
Contact:
Sondra S. Newman
Global Head of Investor Relations
This email address is being protected from spambots. You need JavaScript enabled to view it.
781-250-0111
Last Trade: | US$144.14 |
Daily Change: | -5.07 -3.40 |
Daily Volume: | 887,766 |
Market Cap: | US$8.070B |
July 30, 2024 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB